Lupus nephritis, which can damage and scar the kidneys, is one of the most common and serious complications of lupus. This new study suggests that with the right induction regimen, it may be possible to avoid maintenance (long-term) treatment with oral steroids.
News & Stories
Nick Cannon is a successful entertainer, DJ, entrepreneur, husband, and father. He has always welcomed whatever challenges have come his way. But he wasn’t prepared for the biggest challenge he’d face.
Making gains against lupus kidney disease
The researchers hoped to determine whether differences in genetic ancestry and/or specific genes contribute the decreased risk of developing lupus nephritis among individuals of European descent.
The new SLICC classification rule is more clinically relevant, includes updates and more inclusive definitions of lupus-related variables, and improves upon the ACR classification criteria in several important ways.
To update the ACR guidelines for the management of lupus nephritis, a team of lupus experts from around the country collaborated with the ACR. The researchers utilized extensive literature searches and expert opinions to develop the updated guidelines.
Dr. Diane Kamen of the Medical University of South Carolina provides an overview of how lupus can affect the body's organs.
The use of lupus biomarkers, such as those present in the blood or urine, to help predict and/or manage lupus nephritis over time could be very useful. The results of this study highlight the potential feasibility of using lupus biomarkers to differentiate between acute and chronic kidney disease activity-related changes.
During an appearance on Good Morning America, actor, comedian, and musician Nick Cannon announced that he has lupus nephritis.
The character of Jack O'Malley on USA Network show, "Royal Pains," who was battling lupus, dies after experiencing serious health complications.
In an episode of the USA Network show, Royal Pains, the character of Jack O'Malley is not following his doctor’s directions for treatment of lupus nephritis.
The researchers hoped to learn about whether a protein in the blood called C4d could serve as an indicator of lupus nephritis activity in people with lupus.
Dr. Emily von Scheven of the University of California at San Francisco discusses the development of consensus treatment plans for proliferative nephritis in juvenile systemic lupus.
She may not be faster than a speeding bullet or able to leap tall buildings in a single bound, but Jessica Goldman, 28, is quite the superhero.
The researchers hoped to learn about the relationship between the presence of specific lupus susceptibility genes and the development of specific disease manifestations.
The researchers aimed to determine the effects of the ISN-RPS re-classifications for lupus nephritis on patient outcomes.
Establishing agreement on what constitutes a flare of lupus kidney disease could help identify the true status of the kidney in people with lupus.
Since lupus nephritis can be severe and the therapy can be toxic, it is important to be able to predict which patients would most benefit from long-term treatment.
The researchers hoped to learn whether people with lupus kidney involvement from different races shared the same set of microRNAs.
Current treatments for lupus nephritis in children are toxic and sometimes ineffective. New tests for proteins that might be abnormal in lupus nephritis could help make the diagnosis earlier and might also point to new ways of treating the disease.
Dr. Amy Kao of the Allegheny-Singer Research Institute in Pittsburgh, discusses her research to evaluate the use of CD4 molecules on T-cells as a possible marker for diagnosing lupus nephritis and the potential benefits of a marker for this serious complication of lupus.
Program Provides Individuals the Opportunity to Learn from Leading Lupus Experts.
There are a number of treatments used for lupus nephritis, but none of them are approved by the U.S. Food and Drug Administration (FDA). The researchers hoped to compare the efficacy and safety of MMF and azathioprine as maintenance therapy.
The researchers hoped to determine the specific effects of active lupus-related kidney disease on pregnancy outcomes, as well as complications that might occur in the mothers or babies.
The researchers wanted to compare the effectiveness of mycophenolate mofetil (CellCept) with that of azathioprine to prevent kidney flares after the initial treatment for nephritis was successful.
The researchers hoped to learn about the role of IFNs and macrophages (white blood cells) in the development of experimental lupus nephritis.
The researchers hoped to find out if levels of a protein called TWEAK in samples of the urine or blood could be used to diagnose lupus nephritis.
The researchers hoped to learn whether mRNA in urine samples for the protein made by the FOXP3 gene could be related to lupus kidney disease activity or response to treatment.